arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ZEVRA THERAPEUTICS, INC.

ZVRA
$11.87 ▲ +1.33 (+12.62%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bullish
auto_awesome

Analytical Summary

ZEVRA THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $693.3M
Dividend Yield
Revenue Growth 77.5%
Op. Margin None
ROIC 21.4%
FCF / Share $0.10
Trailing P/E 19.2x
Price / Book 3.4x
FCF Yield 0.9%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 6, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$36.22M
↑ +77.5%
Net Income Profit after all expenses
$37.89M
↑ +211.5%
Operating Margin Operating profit as % of sales
15.9%
↑ +105.8% 4th
FCF / Share Free cash flow per share
$0.10
↑ +40.8%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
41
Returns
97
Financial Health
43
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters